Patents by Inventor Nicolas DAWSON

Nicolas DAWSON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-HLA-A2 ANTIBODIES AND USES THEREOF
    Publication number: 20240067732
    Abstract: The present invention relates to a novel anti-HLA-A2 antibody, and to a chimeric antigen receptor comprising said HLA-A2 antibody. The present invention further relates to an immune cell expressing said chimeric receptor antigen, and to therapeutic uses thereof, in particular for treating or preventing graft rejection or GVHD.
    Type: Application
    Filed: September 27, 2023
    Publication date: February 29, 2024
    Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, SANGAMO THERAPEUTICS FRANCE
    Inventors: Li Zhou, Tobias Abel, François Meyer, Megan Levings, Nicolas Dawson, Caroline Lamarche
  • Anti-HLA-A2 antibodies, related chimeric antigen receptors, and uses thereof
    Patent number: 11814432
    Abstract: The present invention relates to a novel anti-HLA-A2 antibody, and to a chimeric antigen receptor comprising said HLA-A2 antibody. The present invention further relates to an immune cell expressing said chimeric receptor antigen, and to therapeutic uses thereof, in particular for treating or preventing graft rejection or GVHD.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: November 14, 2023
    Assignees: The University of British Columbia, Sangamo Therapeutics France
    Inventors: Li Zhou, Tobias Abel, François Meyer, Megan Levings, Nicolas Dawson, Caroline Lamarche
  • NOVEL ANTI-HLA-A2 ANTIBODIES AND USES THEREOF
    Publication number: 20200283530
    Abstract: The present invention relates to a novel anti-HLA-A2 antibody, and to a chimeric antigen receptor comprising said HLA-A2 antibody. The present invention further relates to an immune cell expressing said chimeric receptor antigen, and to therapeutic uses thereof, in particular for treating or preventing graft rejection or GVHD.
    Type: Application
    Filed: September 20, 2018
    Publication date: September 10, 2020
    Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, SANGAMO THERAPEUTICS FRANCE
    Inventors: Li ZHOU, Tobias ABEL, François MEYER, Megan LEVINGS, Nicolas DAWSON, Caroline LAMARCHE